keyword
MENU ▼
Read by QxMD icon Read
search

hiv long acting injectable

keyword
https://www.readbyqxmd.com/read/28812207/the-vaginal-microbiome-and-its-potential-to-impact-efficacy-of-hiv-pre-exposure-prophylaxis-for-women
#1
REVIEW
Jennifer Velloza, Renee Heffron
PURPOSE OF REVIEW: This review describes existing evidence addressing the potential modulation of pre-exposure prophylaxis (PrEP) products, specifically 1% tenofovir (TFV) gel and oral tenofovir-based PrEP, by vaginal dysbiosis and discusses future considerations for delivering novel, long-acting PrEP products to women at high risk for vaginal dysbiosis and HIV. RECENT FINDINGS: We describe results from analyses investigating the modification of PrEP efficacy by vaginal dysbiosis and studies of biological mechanisms that could render PrEP ineffective in the presence of specific microbiota...
August 15, 2017: Current HIV/AIDS Reports
https://www.readbyqxmd.com/read/28750936/long-acting-injectable-art-next-revolution-in-hiv
#2
Mark A Boyd, David A Cooper
No abstract text is available yet for this article.
July 21, 2017: Lancet
https://www.readbyqxmd.com/read/28750935/long-acting-intramuscular-cabotegravir-and-rilpivirine-in-adults-with-hiv-1-infection-latte-2-96-week-results-of-a-randomised-open-label-phase-2b-non-inferiority-trial
#3
David A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, Joseph J Eron, Yazdan Yazdanpanah, Daniel Podzamczer, Thomas Lutz, Jonathan B Angel, Gary J Richmond, Bonaventura Clotet, Felix Gutierrez, Louis Sloan, Marty St Clair, Miranda Murray, Susan L Ford, Joseph Mrus, Parul Patel, Herta Crauwels, Sandy K Griffith, Kenneth C Sutton, David Dorey, Kimberly Y Smith, Peter E Williams, William R Spreen
BACKGROUND: Cabotegravir and rilpivirine are antiretroviral drugs in development as long-acting injectable formulations. The LATTE-2 study evaluated long-acting cabotegravir plus rilpivirine for maintenance of HIV-1 viral suppression through 96 weeks. METHODS: In this randomised, phase 2b, open-label study, treatment-naive adults infected with HIV-1 initially received oral cabotegravir 30 mg plus abacavir-lamivudine 600-300 mg once daily. The objective of this study was to select an intramuscular dosing regimen based on a comparison of the antiviral activity, tolerability, and safety of the two intramuscular dosing regimens relative to oral cabotegravir plus abacavir-lamivudine...
July 21, 2017: Lancet
https://www.readbyqxmd.com/read/28739783/effect-of-rifampin-on-the-single-dose-pharmacokinetics-of-oral-cabotegravir-in-healthy-subjects
#4
S L Ford, K Sutton, Y Lou, Z Zhang, A Tenorio, C Trezza, P Patel, W Spreen
Introduction: Drug-drug interactions between antiretroviral medications and rifampin complicate the treatment of HIV and tuberculosis coinfection. This study evaluated the effect of rifampin on the pharmacokinetics of oral cabotegravir, an integrase strand transfer inhibitor being investigated for long-acting treatment and prevention of HIV-1 infection.Methods: This was a phase I, single-center, open-label, fixed-sequence crossover study in healthy adults. The objective was to evaluate the effect of steady-state rifampin on the single-dose plasma pharmacokinetics of cabotegravir...
July 24, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28658155/long-term-follow-up-of-elite-controllers-higher-risk-of-complications-with-hcv-coinfection-no-association-with-hiv-disease-progression
#5
Kristen A Stafford, Zahra Rikhtegaran Tehrani, Saman Saadat, Maryam Ebadi, Robert R Redfield, Mohammad M Sajadi
To estimate the effect of hepatitis C virus (HCV) coinfection on the development of complications and progression of human immunodeficiency virus (HIV) disease among HIV-infected elite controllers.Single-center retrospective cohort. Kaplan-Meier methods, prevalence ratios, and Cox proportional-hazards models were used.In all, 55 HIV-infected elite controllers were included in this study. Among them, 45% were HIV/HCV coinfected and 55% were HIV mono-infected. Median follow-up time for the cohort was 11 years...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28615975/pre-exposure-prophylaxis-for-hiv-prevention-in-women-current-perspectives
#6
REVIEW
Charlene A Flash, Sannisha K Dale, Douglas S Krakower
There are ~900,000 new HIV infections among women every year, representing nearly half of all new HIV infections globally. In the US, nearly one-fifth of all new HIV infections occur among women, and women from racial and ethnic minority communities experience disproportionately high rates of new HIV infections. Thus, there is a need to develop and implement effective HIV prevention strategies for women in the US and internationally, with a specific need to advance strategies in minority communities. Previous studies have demonstrated that oral HIV pre-exposure prophylaxis (PrEP), the use of antiretroviral medications by HIV-uninfected persons to prevent HIV acquisition, can reduce HIV incidence among women who are adherent to PrEP...
2017: International Journal of Women's Health
https://www.readbyqxmd.com/read/28612340/long-acting-systemic-hiv-pre-exposure-prophylaxis-an-examination-of-the-field
#7
REVIEW
William R Lykins, Ellen Luecke, Daniel Johengen, Ariane van der Straten, Tejal A Desai
Oral pre-exposure prophylaxis for the prevention of HIV-1 transmission (HIV PrEP) has been widely successful as demonstrated by a number of clinical trials. However, studies have also demonstrated the need for patients to tightly adhere to oral dosing regimens in order to maintain protective plasma and tissue concentrations. This is especially true for women, who experience less forgiveness from dose skipping than men in clinical trials of HIV PrEP. There is increasing interest in long-acting (LA), user-independent forms of HIV PrEP that could overcome this adherence challenge...
June 13, 2017: Drug Delivery and Translational Research
https://www.readbyqxmd.com/read/28577243/review-on-the-biological-mechanisms-associated-with-depo-provera-and-hiv-1-risk-acquisition-in-women
#8
REVIEW
Funanani Takalani, Ndumiso N Mhlongo, Suri Moonsamy, Mahmoud E S Soliman
Women constitute more than 50% out of millions of individuals infected with HIV-1, the major causative agent of acquired immune deficiency syndrome. About 40% of HIV-1 infections have been reported to initiate in the female reproductive tract. However, the mechanisms through which these infections are spread are poorly understood; hence, there is now a major concern in women who use long acting injectable hormonal contraceptives, particularly Depo-Provera and an increase of HIV-1 risk acquisition. Based on literature, Depo-Provera has an affinity for both the glucocorticoid receptor and the progesterone receptor in the female reproductive tract...
June 3, 2017: Cell Biochemistry and Biophysics
https://www.readbyqxmd.com/read/28549121/long-acting-injectable-anti-retroviral-therapy-an-opportunity-to-improve-hiv-treatment-and-reduce-hiv-transmission-among-persons-being-released-from-prison-facilities
#9
Lauren Brinkley-Rubinstein, David L Rosen, Paul Christopher, Lauri Bazerman, Curt G Beckwith
No abstract text is available yet for this article.
May 26, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28546090/safety-and-tolerability-of-long-acting-cabotegravir-injections-in-hiv-uninfected-men-eclair-a-multicentre-double-blind-randomised-placebo-controlled-phase-2a-trial
#10
Martin Markowitz, Ian Frank, Robert M Grant, Kenneth H Mayer, Richard Elion, Deborah Goldstein, Chester Fisher, Magdalena E Sobieszczyk, Joel E Gallant, Hong Van Tieu, Winkler Weinberg, David A Margolis, Krischan J Hudson, Britt S Stancil, Susan L Ford, Parul Patel, Elizabeth Gould, Alex R Rinehart, Kimberly Y Smith, William R Spreen
BACKGROUND: Cabotegravir (GSK1265744) is an HIV-1 integrase strand transfer inhibitor with potent antiviral activity and a long half-life when administered by injection that prevented simian-HIV infection upon repeat intrarectal challenge in male macaques. We aimed to assess the safety, tolerability, and pharmacokinetics of long-acting cabotegravir injections in healthy men not at high risk of HIV-1 infection. METHODS: We did this multicentre, double-blind, randomised, placebo-controlled, phase 2a trial at ten sites in the USA...
August 2017: Lancet HIV
https://www.readbyqxmd.com/read/28527854/barriers-to-initiation-of-extended-release-naltrexone-among-hiv-infected-adults-with-alcohol-use-disorders
#11
Hélène Chokron Garneau, Alexandra Venegas, Richard Rawson, Lara A Ray, Suzette Glasner
Alcohol consumption is a major risk factor for the acquisition of HIV/AIDS and is associated with greater disease burden and mortality among those who become HIV-infected. Of the extant pharmacological treatments for alcohol use disorders, naltrexone is recognized as one of the most efficacious, producing robust reductions in alcohol craving and use. Given that treatment with oral naltrexone has been limited by problems with adherence, which are particularly prevalent among individuals with multiple chronic, co-occurring conditions, long-acting formulations may be a promising approach for HIV-infected substance users...
May 11, 2017: Journal of Substance Abuse Treatment
https://www.readbyqxmd.com/read/28498144/the-impact-of-preexposure-prophylaxis-among-men-who-have-sex-with-men-an-individual-based-model
#12
Parastu Kasaie, Jeff Pennington, Maunank S Shah, Stephen A Berry, Danielle German, Colin P Flynn, Chris Beyrer, David W Dowdy
OBJECTIVES: Preexposure prophylaxis (PrEP) is recommended for preventing HIV infection among individuals at high risk, including men who have sex with men (MSM). Although its individual-level efficacy is proven, questions remain regarding population-level impact of PrEP implementation. DESIGN: We developed an agent-based simulation of HIV transmission among MSM, accounting for demographics, sexual contact network, HIV disease stage, and use of antiretroviral therapy...
June 1, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28368868/universal-antiretroviral-regimens-thinking-beyond-one-pill-once-a-day
#13
Jeffrey M Jacobson, Charles W Flexner
PURPOSE OF REVIEW: Poor adherence to oral antiretroviral treatment in a subpopulation of persons with HIV-1 infection interferes with the potential success of the drug regimens in treating the infection. Here, we review long-acting antiretroviral strategies currently in clinical development that could prove useful for the treatment of HIV-1 infection in individuals not succeeding with short-acting oral regimens. RECENT FINDINGS: Pharmaceutical nanotechnology has succeeded in creating two novel long-acting injectable antiretroviral compounds, carbotegravir and rilpivirine, which have completed early clinical trials demonstrating the safety, tolerability and prolonged antiretroviral activity...
July 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/28356041/recent-advances-in-antiretroviral-agents-potent-integrase-inhibitors
#14
Mina Psichogiou, Garyphalia Poulakou, Dimitrios Basoulis, Dimitrios Paraskevis, Antonios Markogiannakis, George L Daikos
Integrase strand transfer inhibitors (INSTIs) belong to a novel class of antiretroviral agents that have emerged as the new first-line treatments. Three such compounds are currently available, raltegravir, elvitegravir, dolutegravir and two more under development, bictegravir and cabotegravir. These compounds share the same mode of action but exhibit different pharmacokinetic/ pharmacodynamic properties, and drug-drug interactions. A series of studies in the past decade have established their efficacy compared to previous regimens, both in treatment-naïve and experienced patients...
March 29, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28291047/the-impact-of-pre-exposure-prophylaxis-among-men-who-have-sex-with-men-an-individual-based-model
#15
Parastu Kasaie, Jeff Pennington, Maunank S Shah, Stephen A Berry, Danielle German, Colin P Flynn, Chris Beyrer, David W Dowdy
OBJECTIVES: Pre-exposure prophylaxis (PrEP) is recommended for preventing HIV infection among individuals at high risk, including men who have sex with men (MSM). Although its individual-level efficacy is proven, questions remain regarding population-level impact of PrEP implementation. DESIGN: We developed an agent-based simulation of HIV transmission among MSM, accounting for demographics, sexual contact network, HIV disease stage and use of antiretroviral therapy...
March 10, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28285153/contraceptive-method-and-self-reported-hiv-status-among-women-in-malawi
#16
Jamie E Luster, Abigail Norris Turner, Duna Alkhalaileh, Maria F Gallo
OBJECTIVES: We aimed to describe contraceptive methods used by women in Malawi and determine whether contraceptive use differed by self-reported HIV status. Effective contraception is a primary method of preventing mother-to-child transmission of HIV. STUDY DESIGN: Analysis is based on 12,658 nonpregnant, sexually debuted women ages 15-49 years in the 2010 Malawi Demographic and Health Survey. Analysis was restricted to respondents with contraceptive need (i.e., fecund and did not want a child in the next 12 months) who reported their last HIV test result...
June 2017: Contraception
https://www.readbyqxmd.com/read/28121666/tenofovir-alafenamide-and-elvitegravir-loaded-nanoparticles-for-long-acting-prevention-of-hiv-1-vaginal-transmission
#17
Subhra Mandal, Pavan K Prathipati, Guobin Kang, You Zhou, Zhe Yuan, Wenjin Fan, Qingsheng Li, Christopher J Destache
OBJECTIVE: This report presents tenofovir (TFV) alafenamide (TAF) and elvitegravir (EVG) fabricated into nanoparticles for subcutaneous delivery as prevention strategy. DESIGN: Prospective prevention study in humanized bone marrow-liver-thymus (hu-BLT) mice. METHODS: Using an oil-in-water emulsion solvent evaporation technique, TAF + EVG drugs were entrapped together into nanoparticles containing poly(lactic-co-glycolic acid). In-vitro prophylaxis studies (90% inhibition concentration) compared nanoparticles with drugs in solution...
February 20, 2017: AIDS
https://www.readbyqxmd.com/read/28011389/extended-release-naltrexone-for-pre-release-prisoners-a-randomized-trial-of-medical-mobile-treatment
#18
Michael S Gordon, Frank J Vocci, Terrence T Fitzgerald, Kevin E O'Grady, Charles P O'Brien
BACKGROUND: Extended-release naltrexone (XR-NTX), is an effective treatment for opioid use disorder but is rarely initiated in US prisons or with criminal justice populations. Mobile treatment for chronic diseases has been implemented in a variety of settings. Mobile treatment may provide an opportunity to expand outreach to parolees to surmount barriers to traditional clinic treatment. METHODS: Male and female prisoners (240) with pre-incarceration histories of opioid use disorder who are within one month of release from prison will be enrolled in this randomized clinical trial...
February 2017: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/27799824/profile-of-cabotegravir-and-its-potential-in-the-treatment-and-prevention-of-hiv-1-infection-evidence-to-date
#19
REVIEW
Thomas Whitfield, Adele Torkington, Clare van Halsema
Modern antiretroviral therapy has demonstrated effectiveness in preexposure prophylaxis (PrEP) and treatment of HIV infection. There is a demand for prevention and treatment regimens that could overcome challenges of improving adherence, toxicity, and dosing convenience. Cabotegravir is an integrase strand transfer inhibitor and an analog of dolutegravir. Unlike dolutegravir, cabotegravir has a long half-life and can be formulated into a long-acting nanosuspension for parenteral administration. Initial pharmokinetic studies in humans have demonstrated adequate drug levels with intramuscular (IM) administration at 4 weekly and 8 weekly intervals, with few interactions with commonly used concomitant medications...
2016: HIV/AIDS: Research and Palliative Care
https://www.readbyqxmd.com/read/27771050/progress-in-formulation-based-approaches-for-antiretrovirals
#20
Ameya R Kirtane, Robert Langer, Giovanni Traverso
The human immunodeficiency virus has infected millions of people and the epidemic continues to grow rapidly in some parts of the world. Antiretroviral (ARV) therapy has provided improved treatment and prolonged the life expectancy of patients. Moreover, there is growing interest in using ARVs to protect against new infections. Hence, ARVs have emerged as our primary strategy in combating the virus. Unfortunately, several challenges limit the optimal performance of these drugs. First, ARVs often require life-long use and complex dosing regimens...
October 19, 2016: Journal of Pharmaceutical Sciences
keyword
keyword
114592
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"